Apr. 4—ALBANY — In the first three months of its use at Phoebe, monoclonal antibody infusion therapy has shown outstanding results for COVID-19 patients at high risk of developing severe illness. The therapy was part of President Trump’s treatment regimen when it was in an experimental stage last October. The following month, the Food and Drug Administration gave the treatment emergency use authorization, and Phoebe began providing the therapy to approved patients in early January.
“The therapy is approved for high-risk patients soon after their diagnosis,” Phoebe Putney Health System Chief Medical Officer Dr. Dianna Grant said. “The goal is to help those patients avoid emergency room visits and hospital stays, and that is exactly what we are achieving with our use of the treatment at Phoebe.”
Through April 1, Phoebe has provided the treatment to 194 patients at Phoebe North and 75 at Phoebe Sumter.
“Only two of the